Armata Pharmaceuticals – BioScience Managers

Armata Pharmaceuticals Announces $20 Million Investment to Support Advancement of the Company’s Bacteriophage Development Programs

27th January 2021/in Armata Pharmaceuticals

Link to Full Article MARINA DEL REY, Calif., Jan. 27, 2021 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has entered into a securities purchase agreement to sell Armata common stock and warrant securities to Innoviva […]

Armata Pharmaceuticals Announces the Addition of Robin C. Kramer to its Board of Directors

9th December 2020/in Armata Pharmaceuticals

Link to Full Article Biogen Chief Accounting Officer adds significant financial leadership experience MARINA DEL REY, Calif., Dec. 9, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Robin C. Kramer was elected by the Armata shareholders […]

Armata Pharmaceuticals Issues Letter to Shareholders

29th October 2020/in Armata Pharmaceuticals

Link to Full Article MARINA DEL REY, Calif., Oct. 29, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata”), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today issued the following letter to shareholders. The letter has been made available to all existing shareholders with the Proxy for the […]

Armata Pharmaceuticals Appoints Mina Pastagia, MD, MS as Vice President of Clinical Development

26th October 2020/in Armata Pharmaceuticals

Link to Full Article Appointment adds extensive expertise in the development of anti-infectives, including bacteriophage therapy to treat P. aeruginosa infections in cystic fibrosis patients MARINA DEL REY, Calif., Oct. 26, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat […]

Armata Pharmaceuticals Announces Clearance of Investigational New Drug (IND) Application to Initiate Phase 1b/2a Clinical Trial of Lead Candidate AP-PA02 in Pseudomonas aeruginosa Infections

15th October 2020/in Armata Pharmaceuticals

Link to Full Article Upcoming study, to be known as “SWARM-P.a.,” is believed to be first FDA cleared, controlled clinical trial to evaluate a multiple phage-based mixture as a therapeutic candidate in Cystic Fibrosis patients MARINA DEL REY, Calif., Oct. 15, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused […]

Armata Pharmaceuticals Announces Second Quarter 2020 Results and Provides General Corporate Update

13th August 2020/in Armata Pharmaceuticals

Link to Full Article MARINA DEL REY, Calif., Aug. 13, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced results for the second quarter of 2020 and provided a corporate and clinical update. During the […]

Armata Pharmaceuticals Announces $15 Million Award from the U.S. Department of Defense (DoD) for Development of Bacteriophage Therapy to Treat S. aureus Bacteremia Infections

17th June 2020/in Armata Pharmaceuticals

Link to Full Article Non-dilutive funding to be used to advance the company’s second phage-based therapeutic candidate in a Phase 1b/2 clinical study MARINA DEL REY, Calif., June 17, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today […]

Armata Pharmaceuticals Announces First Quarter 2020 Results and Provides General Corporate Update

14th May 2020/in Armata Pharmaceuticals

Link to Full Article MARINA DEL REY, Calif., May 14, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced results for the first quarter of 2020 and provided a corporate and clinical update. Key First Quarter 2020 and Subsequent […]

Armata Pharmaceuticals Announces Closing of Second Tranche of $25 Million Securities Purchase Agreement with Innoviva, Inc.

30th March 2020/in Armata Pharmaceuticals

Link to Full Article – Funds to be used primarily to advance its lead Pseudomonas aeruginosa candidate, AP-PA02 MARINA DEL REY, Calif., March 30, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that, following a vote in favor […]

Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Results and Provides General Corporate Update

19th March 2020/in Armata Pharmaceuticals

Link to Full Article MARINA DEL REY, Calif., March 19, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced results for the fourth quarter and full year 2019 and provided a corporate and clinical update. Key Fourth Quarter and […]